Russell Conley’s loss will no doubt be felt deeply across the GI Cancer Community
On the demise of Russell Conley on November 27th, a post from his LinkedIn account informed the LinkedIn community about his passing. The post read as follows:
“It is with great sadness that we share the news of Russell Conley‘s passing. His loss will no doubt be felt deeply across the GI cancer community and by all the friends and connections he made during his 20+ years at AGITG.
Whether it was with researchers, industry colleagues or patient advocates, Russell’s passion and energy left a lasting impression with all and helped him build the organisation to the strengths it sees today.
Over 70 research studies were conducted during Russell’s 22 years at the helm of AGITG. These trials directly benefited more than 8,000 people with GI cancer. But the impact of these trials was felt by far more – many of these trials were significant practice-changing trials that changed how people with GI cancer are now treated for the better.
Always putting the patient first, Russell was crucial in the establishment of the Community Advisory Panel and ensured that the Committee’s contribution was valued by researchers. He also supported the launch of the Engage community event program to provide better education and support for patients and their families.
When Russell joined the AGITG back in 2002, there were less than 200 members. During his tenure, the membership flourished, welcoming new disciplines and becoming increasingly multi-disciplinary. There are now more than 1,800 members involved in the Group.
One of Russell’s key strengths was developing relationships. He grew partnerships with many local patient advocacy organisations and with the 13 other Australian collaborative trials groups. Russell expanded the Group’s connections outside of Australia and Aotearoa New Zealand, into the US, UK, Europe and Asia, resulting in AGITG trials now being conducted at over 285 sites globally.
Russell willingly took on every opportunity to progress GI cancer research. He volunteered extensive time to attend and speak at community events, and more recently, played an active role in advocating for Australians with rare cancers. Russell openly shared his personal cancer journey to not only help others, but to help raise vital funds for new research. He even climbed mountains, taking on the Mt Kosciuszko Gutsy Challenge.
Russell dedicated his life to improving outcomes for people with GI cancer. We hope his memory will inspire the research community to continue advancing your important work and ensure his legacy lives on.
Click here to make a donation in Russell’s memory and help save lives by advancing research.”
Source: gicancer.org.au
For more Updates, Follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023